Virax Biolabs Group Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-5.03	-6.07	-6.74	-5.46	-1.75
Depreciation & Amortization	0.36	0.27	0.05	-	-
Stock-Based Compensation	0.13	0.37	1.01	1.75	0.29
Other Adjustments	-0.34	0.25	0.55	-0.29	0.01
Change in Receivables	-	-	-	-	0
Changes in Inventories	0.09	-0.03	-0.06	0.02	0
Changes in Accounts Payable	-0.01	0.47	-0.57	0.03	0.64
Changes in Unearned Revenue	-	-	-0.04	0.04	-
Changes in Other Operating Activities	0.18	0.19	-0.6	-0.28	0
Operating Cash Flow	-4.62	-4.56	-6.4	-4.18	-0.81
Capital Expenditures	-0.26	-0.6	-0.95	-	-
Purchases of Intangible Assets	-	-	-0.21	-0.18	-
Investing Cash Flow	-0.26	-0.6	-1.16	-0.18	-
Long-Term Debt Issued	-	-	-	0.49	0.1
Long-Term Debt Repaid	-	-	-	-0.34	-
Net Long-Term Debt Issued (Repaid)	-	-	-	0.15	0.1
Issuance of Common Stock	7.2	5.91	1.87	13.65	0.52
Net Common Stock Issued (Repurchased)	7.2	5.91	1.87	13.65	0.52
Other Financing Activities	-0.11	-0.11	-0.07	-0.11	0.19
Financing Cash Flow	7.09	5.81	1.8	13.69	0.81
Net Cash Flow	2.21	0.64	-5.76	9.33	0
Free Cash Flow	-4.88	-5.17	-7.35	-4.18	-0.81
FCF Margin	-39263.60%	-81621.60%	-4698.55%	-48823.40%	-
Free Cash Flow Per Share	-12.27	-34.63	-91.57	-98.30	-21.15
Levered Free Cash Flow	-4.66	-5.77	-8.9	-5.49	-0.97
Unlevered Free Cash Flow	-5.06	-5.65	-8.69	-5.92	-1.09

SEC Filings: 10-K · 10-Q

Virax Biolabs Group Cash Flow Statement Data Source